{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:45:11Z","timestamp":1792043111803,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40257-020-00505-3","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T17:04:27Z","timestamp":1580403867000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption"],"prefix":"10.1007","volume":"21","author":[{"given":"Shreya","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Zachary","family":"Handler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3036-3825","authenticated-orcid":false,"given":"Robert A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"5","key":"505_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/cod.13351","volume":"81","author":"N Ben Fadhel","year":"2019","unstructured":"Ben Fadhel N, Chaabane A, Ammar H, Ben Romdhane H, Soua Y, Chadli Z, et al. Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermat. 2019;81(5):336\u201340.","journal-title":"Contact Dermat."},{"key":"505_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-1-4471-6729-7_17","volume-title":"Cutaneous drug eruptions","author":"KM Pretzlaff","year":"2015","unstructured":"Pretzlaff KM, Pandya AG, Dominguez AR. Fixed Drug Eruptions. In: Hall JC, Hall BJ, editors. Cutaneous drug eruptions. London: Springer; 2015. p. 181\u201392."},{"issue":"4","key":"505_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bjd.12133","volume":"168","author":"S Lipowicz","year":"2013","unstructured":"Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013;168(4):726\u201332.","journal-title":"Br J Dermatol."},{"issue":"5","key":"505_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.therap.2019.01.009","volume":"74","author":"A Zaouak","year":"2019","unstructured":"Zaouak A, Ben Salem F, Ben Jannet S, Hammami H, Fenniche S. Bullous fixed drug eruption: a potential diagnostic pitfall: a study of 18 cases. Therapie. 2019;74(5):527\u201330.","journal-title":"Therapie."},{"issue":"7","key":"505_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D3237035734","volume":"23","author":"V Mitre","year":"2017","unstructured":"Mitre V, Applebaum DS, Albahrani Y, Hsu S. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review. Dermatol Online J. 2017;23(7):1\u20134.","journal-title":"Dermatol Online J."},{"key":"505_CR6","first-page":"818","volume":"2","author":"D Bourns","year":"1889","unstructured":"Bourns D. Unusual effects of antipyrine. Br Med J. 1889;2:818\u201320.","journal-title":"Br Med J."},{"key":"505_CR7","first-page":"308","volume":"5","author":"L Brocq","year":"1894","unstructured":"Brocq L. Erupo erythemato pigment\u00e9e fix\u00e9 due to antipyrone. Ann Dermatol Syphyligr. 1894;5:308.","journal-title":"Ann Dermatol Syphyligr."},{"issue":"3","key":"505_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","volume":"70","author":"Y-T Cho","year":"2014","unstructured":"Cho Y-T, Lin J-W, Chen Y-C, et al. Generalized bullous fixed drug eruption is distinct from Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70(3):539\u201348.","journal-title":"J Am Acad Dermatol."},{"issue":"11","key":"505_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.14423\/SMJ.0000000000000195","volume":"107","author":"H Flowers","year":"2014","unstructured":"Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis, and management. South Med J. 2014;107(11):724\u20137.","journal-title":"South Med J."},{"key":"505_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1365-2133.1990.tb06275.x","volume":"122","author":"A Lyell","year":"1990","unstructured":"Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol. 1990;122:837\u20138.","journal-title":"Br J Dermatol"},{"key":"505_CR11","doi-asserted-by":"publisher","first-page":"2013200584","DOI":"10.1136\/bcr-2013-200584","volume":"2014","author":"RD Patell","year":"2014","unstructured":"Patell RD, Dosi RV, Shah PC, Joshi HS. Widespread bullous fixed drug eruption. BMJ Case Rep. 2014;2014:2013200584.","journal-title":"BMJ Case Rep."},{"issue":"1","key":"505_CR12","first-page":"45","volume":"90","author":"A Khaled","year":"2012","unstructured":"Khaled A, Kharfi M, Ben HM, et al. Cutaneous adverse drug reactions in children. A series of 90 cases. La Tunisie Medicale. 2012;90(1):45\u201350.","journal-title":"La Tunisie Medicale."},{"issue":"2","key":"505_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1525-1470.1995.tb00149.x","volume":"12","author":"VK Sharma","year":"1995","unstructured":"Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in North India. Pediatr Dermatol. 1995;12(2):178\u201383.","journal-title":"Pediatr Dermatol."},{"key":"505_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511547393","volume-title":"Consultations in dermatology: studies of orphan and unique patients","author":"WB Shelley","year":"2006","unstructured":"Shelley WB, Shelley ED. Consultations in dermatology: studies of orphan and unique patients. Cambridge: Cambridge University Press; 2006."},{"issue":"4","key":"505_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/ijp.IJP_760_16","volume":"50","author":"R Tripathy","year":"2018","unstructured":"Tripathy R, Pattnaik KP, Dehury S, Patro S, Mohanty P, Sahoo SS, Mohanty S. Cutaneous adverse drug reactions with fixed-dose combinations: special reference to self-medication and preventability. Indian J Pharmacol. 2018;50(4):192\u20136.","journal-title":"Indian J Pharmacol."},{"issue":"11","key":"505_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1046\/j.1365-4362.1998.00451.x","volume":"37","author":"A Mahboob","year":"1998","unstructured":"Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37(11):833\u20138.","journal-title":"Int J Dermatol."},{"key":"505_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/archdermatol.2010.419","volume":"147","author":"MD Hermida","year":"2011","unstructured":"Hermida MD, Consalvo L, Lapadula MM, et al. Bullous fixed drug eruption induced by intravaginal metronidazole ovules, with positive topical provocation test findings. Arch Dermatol. 2011;147:250\u20131.","journal-title":"Arch Dermatol"},{"issue":"3","key":"505_CR18","first-page":"201","volume":"17","author":"T Shiohara","year":"2007","unstructured":"Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007;17(3):201\u20138.","journal-title":"Eur J Dermatol."},{"issue":"4","key":"505_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","volume":"9","author":"T Shiohara","year":"2009","unstructured":"Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316\u201321.","journal-title":"Curr Opin Allergy Clin Immunol."},{"issue":"4","key":"505_CR20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S0002-9440(10)64410-0","volume":"161","author":"Y Mizukawa","year":"2002","unstructured":"Mizukawa Y, Yamazaki Y, Teraki Y, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002;161(4):1337\u201347.","journal-title":"Am J Pathol."},{"issue":"2","key":"505_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12016-014-8421-3","volume":"49","author":"T Shiohara","year":"2015","unstructured":"Shiohara T, Ushigome Y, Kano Y, Takahashi R. Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):192\u2013202.","journal-title":"Clin Rev Allergy Immunol."},{"issue":"2","key":"505_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1046\/j.1365-4362.2002.01405.x","volume":"41","author":"H Li","year":"2002","unstructured":"Li H, Wiederkehr M, Rao BK, et al. Peculiar unilateral fixed drug eruption of the breast. Int J Dermatol. 2002;41(2):96\u20138.","journal-title":"Int J Dermatol."},{"issue":"6","key":"505_CR23","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","volume":"158","author":"Y Mizukawa","year":"2008","unstructured":"Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol. 2008;158(6):1230\u20138.","journal-title":"Br J Dermatol."},{"key":"505_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00281-015-0540-2","volume":"38","author":"W Hoetzenecker","year":"2016","unstructured":"Hoetzenecker W, N\u00e4geli M, Mehra E, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38:75\u201386.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"505_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2014.07.010","volume":"76","author":"T Nomura","year":"2014","unstructured":"Nomura T, Kabashima K, Miyachi Y. The panoply of \u03b1\u03b2T cells in the skin. J Dermatol Sci. 2014;76(1):3\u20139.","journal-title":"J Dermatol Sci."},{"issue":"1","key":"505_CR26","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1208\/aapsj080103","volume":"8","author":"M Pirmohamed","year":"2006","unstructured":"Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J. 2006;8(1):E20\u20136.","journal-title":"AAPS J."},{"issue":"3","key":"505_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1610-0387.2007.06491.x","volume":"6","author":"E \u00d6zkaya","year":"2008","unstructured":"\u00d6zkaya E. Fixed drug eruption: state of the art. Journal der Deutschen Dermatologischen Gesellschaft. 2008;6(3):181\u20138.","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft."},{"issue":"9","key":"505_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jdcr.2018.07.013","volume":"4","author":"RC Byrd","year":"2018","unstructured":"Byrd RC, Mournighan KJ, Baca-Atlas M, Helton MR, Sun NZ, Siegel MB. Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Rep. 2018;4(9):953\u20135.","journal-title":"JAAD Case Rep."},{"issue":"2","key":"505_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cger.2013.01.008","volume":"29","author":"AM Ahmed","year":"2013","unstructured":"Ahmed AM, Pritchard S, Reichenberg J. A review of cutaneous drug eruptions. Clin Geriatr Med. 2013;29(2):527\u201345.","journal-title":"Clin Geriatr Med."},{"issue":"12","key":"505_CR30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D35CZ3R80B","volume":"15","author":"JL Hager","year":"2009","unstructured":"Hager JL, Mir MR, Hsu S. Fluoroquinolone-induced generalized fixed drug eruption. Dermatol Online J. 2009;15(12):8.","journal-title":"Dermatol Online J."},{"issue":"1","key":"505_CR31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5826\/dpc.0101a09","volume":"1","author":"W Weyers","year":"2011","unstructured":"Weyers W, Metze D. Histopathology of drug eruptions\u2013general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept. 2011;1(1):33.","journal-title":"Dermatol Pract Concept."},{"issue":"4","key":"505_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/ijd.IJD_431_18","volume":"64","author":"HS Mithari","year":"2019","unstructured":"Mithari HS, Gole PV, Kharkar VD, Mahajan SA. Generalized bullous fixed drug eruption to fluconazole; with cross-reactivity to tinidazole. Indian J Dermatol. 2019;64(4):335\u20137.","journal-title":"Indian J Dermatol."},{"issue":"5","key":"505_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jemermed.2014.09.049","volume":"48","author":"FM Dharamsi","year":"2015","unstructured":"Dharamsi FM, Michener MD, Dharamsi JW. Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome. J Emerg Med. 2015;48(5):551\u20134.","journal-title":"J Emerg Med."},{"issue":"3","key":"505_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.dsi.2015.12.003","volume":"34","author":"B Sereflican","year":"2016","unstructured":"Sereflican B, Ozden HK, Goksugur N, Boran C, Parlak AH. Levofloxacin-induced generalized bullous fixed drug eruption. Dermatol Sin. 2016;34(3):164\u20135.","journal-title":"Dermatol Sin."},{"issue":"8","key":"505_CR35","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1365-4632.2006.02853.x","volume":"45","author":"VN Sehgal","year":"2006","unstructured":"Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006;45(8):897\u2013908.","journal-title":"Int J Dermatol."},{"key":"505_CR36","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/jdv.12919","volume":"29","author":"YK Heng","year":"2015","unstructured":"Heng YK, Yew YW, Lim DS, Lim YL. An update of fixed drug eruptions in Singapore. J Eur Acad Dermatol Venereol. 2015;29:1539\u201344.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"505_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1600-0536.2011.01946.x","volume":"65","author":"P Andrade","year":"2011","unstructured":"Andrade P, Brinca A, Gon\u00e7alo M. Patch testing in fixed drug eruptions: a 20-year review. Contact Dermat. 2011;65(4):195\u2013201.","journal-title":"Contact Dermat."},{"issue":"2","key":"505_CR38","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jaad.2012.08.019","volume":"69","author":"E \u00d6zkaya","year":"2013","unstructured":"\u00d6zkaya E. Oral mucosal fixed drug eruption: characteristics and differential diagnosis. J Am Acad Dermatol. 2013;69(2):e51\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"505_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0960327111412804","volume":"31","author":"S Bilgili","year":"2012","unstructured":"Bilgili S, Calka O, Karadag A, Akdeniz N, Kosem M. Nonsteroidal anti-inflammatory drugs-induced generalized fixed drug eruption: two cases. Hum Exp Toxicol. 2012;31(2):197\u2013200.","journal-title":"Hum Exp Toxicol."},{"issue":"3","key":"505_CR40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jaip.2015.12.005","volume":"4","author":"V Bellini","year":"2016","unstructured":"Bellini V, Bianchi L, Hansel K, Finocchi R, Stingeni L. Bullous nonpigmenting multifocal fixed drug eruption due to pseudoephedrine in a combination drug: clinical and diagnostic observations. J Allergy Clin Immunol Pract. 2016;4(3):542\u20134.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"505_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4168\/aair.2012.4.5.309","volume":"4","author":"M-H Kim","year":"2012","unstructured":"Kim M-H, Shim E-J, Jung J-W, Sohn S-W, Kang H-R. A case of allopurinol-induced fixed drug eruption confirmed with a lymphocyte transformation test. Allergy Asthma Immunol Res. 2012;4(5):309.","journal-title":"Allergy Asthma Immunol Res."},{"issue":"1","key":"505_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s40800-017-0067-7","volume":"5","author":"S Demir","year":"2018","unstructured":"Demir S, Cetin EA, Unal D, et al. Generalized fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole: lymphocyte transformation test confirms the diagnosis. Drug Saf Case Rep. 2018;5(1):2.","journal-title":"Drug Saf Case Rep."},{"key":"505_CR43","volume-title":"Inflammatory diseases of the dermis and epidermis. Dermatopathology","author":"MA Fung","year":"2010","unstructured":"Fung MA. Inflammatory diseases of the dermis and epidermis. Dermatopathology. Amsterdam: Elsevier Inc.; 2010."},{"issue":"2","key":"505_CR44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4168\/aair.2017.9.2.182","volume":"9","author":"KH Sohn","year":"2017","unstructured":"Sohn KH, Kim BK, Kim JY, Song WJ, Kang HR, Park HW, et al. Fixed food eruption caused by Actinidia arguta (Hardy Kiwi): a case report and literature review. Allergy Asthma Immunol Res. 2017;9(2):182\u20134.","journal-title":"Allergy Asthma Immunol Res."},{"key":"505_CR45","unstructured":"Janusz SC, Schwartz RA. Phytophotodermatitis: an occupational and recreational dermatosis in the limelight. Cutis (in press)."},{"issue":"2","key":"505_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000063891","volume":"205","author":"T Shiohara","year":"2002","unstructured":"Shiohara T, Mizukawa Y. Fixed drug eruption: easily overlooked but needing new respect. Dermatology. 2002;205(2):103\u20134.","journal-title":"Dermatology."},{"issue":"6","key":"505_CR47","first-page":"AB13","volume":"76","author":"L Croda","year":"2017","unstructured":"Croda L, Valentin M, Caufield M, Goldberg M, Pasieka H. A diagnostic dilemma: a case of generalized bullous fixed drug eruption versus Stevens\u2013Johnson syndrome: 4249. J Am Acad Dermatol. 2017;76(6):AB13.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"505_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.dsi.2012.02.002","volume":"30","author":"C-H Lee","year":"2012","unstructured":"Lee C-H, Chen Y-C, Cho Y-T, Chang C-Y, Chu C-Y. Fixed-drug eruption: a retrospective study in a single referral center in northern Taiwan. Dermatol Sin. 2012;30(1):11\u20135.","journal-title":"Dermatol Sin."},{"issue":"5","key":"505_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2133.1985.tb15266.x","volume":"112","author":"K Kauppinen","year":"1985","unstructured":"Kauppinen K, Stubb S. Fixed eruptions: causative drugs and challenge tests. Br J Dermatol. 1985;112(5):575\u20138.","journal-title":"Br J Dermatol."},{"issue":"12","key":"505_CR50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/cup.13563","volume":"46","author":"JR Bakke","year":"2019","unstructured":"Bakke JR, Chantara A, Cash J, Fisher KR. Vancomycin-induced linear IgA bullous dermatosis presenting as generalized fixed drug eruption. J Cutan Pathol. 2019;46(12):979\u201381.","journal-title":"J Cutan Pathol."},{"key":"505_CR51","first-page":"173","volume":"69","author":"RA Schwartz","year":"2013","unstructured":"Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173\u201384.","journal-title":"J Am Acad Dermatol"},{"key":"505_CR52","first-page":"187","volume":"69","author":"RA Schwartz","year":"2013","unstructured":"Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187\u2013202.","journal-title":"J Am Acad Dermatol"},{"key":"505_CR53","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/jdv.12541","volume":"28","author":"MZ Handler","year":"2014","unstructured":"Handler MZ, Schwartz RA. Staphlococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol. 2014;28:1418\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"505_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/120347540100500604","volume":"5","author":"AJ Papadopoulos","year":"2001","unstructured":"Papadopoulos AJ, Schwartz RA, Fekete Z, Kihiczak G, Samady JA, Atkin SH, et al. Pseudoporphyria. An atypical variant resembling toxic epidermal necrolysis. J Cutan Med Surg. 2001;5:479\u201385.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"505_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","volume":"65","author":"Y Fujita","year":"2011","unstructured":"Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2011;65(1):65\u20138.","journal-title":"J Am Acad Dermatol."},{"key":"505_CR56","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1258\/0956462041558285","volume":"15","author":"V Zawar","year":"2004","unstructured":"Zawar V, Kirloskar M, Chuh A. Fixed drug eruption: a sexually inducible reaction? Int J STD AIDS. 2004;15:560\u20133.","journal-title":"Int J STD AIDS."},{"issue":"5","key":"505_CR57","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4103\/ijd.IJD_458_17","volume":"63","author":"R Beniwal","year":"2018","unstructured":"Beniwal R, Gupta LK, Khare AK, Mittal A, Mehta S, Balai M. Cyclosporine in generalized bullous-fixed drug eruption. Indian J Dermatol. 2018;63(5):432\u20133.","journal-title":"Indian J Dermatol."},{"issue":"2","key":"505_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D3232033968","volume":"23","author":"N Malviya","year":"2017","unstructured":"Malviya N, Cyrus N, Vandergriff T, Mauskar M. Generalized bullous fixed drug eruption treated with cyclosporine. Dermatol Online J. 2017;23(2):1\u20133.","journal-title":"Dermatol Online J."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00505-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:40:32Z","timestamp":1722375632000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00505-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00505-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"30 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Shreya Patel, Ann M. John, Marc Zachary Handler, and Robert A. Schwartz have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}